Commentary: safety of anti-TNF use in pregnancy

被引：0
|
作者：
Hart, Ailsa [1 ]
机构：
[1] St Marks Hosp, IBD Unit, Harrow, Middx, England
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 51卷 / 01期
关键词：
INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB; CONSENSUS;
D O I：
10.1111/apt.15548
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THIS IS A SPECIAL COMMENTARY ON "INTENTIONAL INFLIXIMAB USE DURING PREGNANCY FOR INDUCTION OR MAINTENANCE OF REMISSION IN CROHN'S DISEASE" BY MAHADEVAN, U., KANE, S., SANDBORN, W.J., COHEN, R.D., HANSON, K., TERDIMAN, J.P., AND BINION, D.G., ORIGINALLY PUBLISHED IN AP&T IN 2005. DOI:
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [31] Safety of anti-TNFα therapy in children with juvenile idiopathic arthritis
    Dekker, L
    Armbrust, W
    Rademaker, CMA
    Prakken, B
    Kuis, W
    Wulffraat, NM
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (02) : 252 - 258
  • [32] Abatacept and anti-TNF monoclonal antibodies: efficacy and safety comparisons
    Schiff, M.
    Dougados, M.
    Fleischmann, R.
    Fay, J.
    Maldonado, M.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 103 - 103
  • [33] Safety of Anti-TNF Alpha Agents in the Pregnant Psoriatic Patient
    Shallcross, Laurie K.
    Driscoll, Marcia S.
    [J]. CURRENT DRUG THERAPY, 2013, 8 (01) : 45 - 58
  • [34] Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis
    Girolomoni, Giampiero
    Altomare, Gianfranco
    Ayala, Fabio
    Berardesca, Enzo
    Calzavara-Pinton, Piergiacomo
    Chimenti, Sergio
    Peserico, Andrea
    Guerra, Antonio Puglisi
    Vena, Gino Antonio
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2012, 34 (04) : 548 - 560
  • [35] Anti-TNF alpha
    Faure, Sebastien
    [J]. ACTUALITES PHARMACEUTIQUES, 2010, 49 (500): : 51 - 54
  • [36] Anti-TNF Therapy
    Udalova, Irina
    Monaco, Claudia
    Nanchahal, Jagdeep
    Feldmann, Marc
    [J]. MICROBIOLOGY SPECTRUM, 2016, 4 (04):
  • [37] Anti-TNF therapy
    Thalayasingam, Nishanthi
    Isaacs, John D.
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 549 - 567
  • [38] The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
    Allez, M.
    Vermeire, S.
    Mozziconacci, N.
    Michetti, P.
    Laharie, D.
    Louis, E.
    Bigard, M. -A.
    Hebuterne, X.
    Treton, X.
    Kohn, A.
    Marteau, P.
    Cortot, A.
    Nichita, C.
    van Assche, G.
    Rutgeerts, P.
    Lemann, M.
    Colombel, J. -F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) : 92 - 101
  • [39] Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type
    Kanis, Shannon L.
    de Lima-Karagiannis, Alison
    van der Ent, Cokkie
    Rizopoulos, Dimitris
    van der Woude, C. Janneke
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 (08): : 939 - 947
  • [40] What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?
    Cerpa Arencibia, A.
    Suarez Ferrer, C.
    Poza Cordon, J.
    Martin Arranz, E.
    Ramirez, L.
    Martin Arranz, M. D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S554 - S554
12345